BUYINS.NET Updates TherapeuticsMD SqueezeTrigger Report
M2 - Thu Apr 17, 8:13AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has updated coverage on TherapeuticsMD (NYSE MKT: TXMD) after releasing the latest short sale data through April 15, 2014. The total aggregate number of shares shorted since November 2011 is approximately 48.7 million shares. Approximately 26.22% of daily trading volume is short selling. The SqueezeTrigger price for all TXMD shares shorted is $4.91. A short squeeze is expected to begin when shares of TXMD close above the $4.91 SqueezeTrigger Price.
TherapeuticsMD Reports Positive Results of Rabbit Irritation Study for Its Estradiol Vaginal Capsule VagiCap(TM) (TX 004-HR) for Treatment of Vulvar Vaginal Atrophy (VVA)
Business Wire - Mon Apr 07, 3:05PM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's healthcare company ("TherapeuticsMD" or the "Company"
BocaGreenMD Launches Prena1 Pearl(TM), the Only Generic Version of vitaMedMD's vitaPearl(TM)
Business Wire - Mon Apr 07, 6:15AM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD) ("TherapeuticsMD" or the "Company"
Analytical Notes on Health Care Equities -- Research on TherapeuticsMD, China Pharma Holdings, Pacira Pharma, and Lannett
PR Newswire - Wed Mar 26, 10:15AM CDT
The trading session on Tuesday, March 25, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,367.88, up 0.56% and the NASDAQ Composite closed at 4,234.27, up 0.19%. The S&P 500 finished the session 0.44% higher at 1,865.62. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day 0.83% higher at 671.69, while the same has advanced 5.27% in the last three months. Investor-Edge has initiated coverage on the following equities: TherapeuticsMD Inc. (NYSE MKT: TXMD), China Pharma Holdings Inc. (NYSE MKT: CPHI), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Lannett Co. Inc. (NYSE: LCI). Free technical research on TXMD, CPHI, PCRX, and LCI can be downloaded upon signing up at:
TherapeuticsMD Announces Pricing of Secondary Offering
Business Wire - Thu Mar 20, 4:36PM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD) (the "Company"
Therapeutics to offer 9m shares in secondary public offering
M2 - Wed Mar 19, 7:41AM CDT
Healthcare company Therapeutics (NYSE MKT:TXMD) reported on Tuesday that it intends to start a secondary public offering of 9,000,000 shares of its common stock.
vitaMedMD Launches vitaPearl(TM), The Smallest Complete Prescription Prenatal Multivitamin With FOLMAX(TM), FePlus(TM), and pur-DHA(TM)
Business Wire - Wed Mar 19, 6:00AM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD) ("TherapeuticsMD" or the "Company"
TherapeuticsMD Announces Launch of Secondary Offering
Business Wire - Tue Mar 18, 3:02PM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD) (the "Company"
TherapeuticsMD Reports Fourth Quarter and Full-Year 2013 Results
Business Wire - Mon Mar 03, 3:05PM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's healthcare company, ("TherapeuticsMD" or the "Company"
TherapeuticsMD to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Tue Feb 25, 3:30PM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's healthcare company ("TherapeuticsMD" or the "Company"
TherapeuticsMD To Host Conference Call and Live Audio Webcast to Disclose Financial Results for Quarter and Year Ended December 31, 2013
Business Wire - Tue Feb 25, 6:01AM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's healthcare company ("TherapeuticsMD" or the "Company"
'Mad Money' Lightning Round: Don't Bet on Boyd Gaming
at The Street - Fri Jan 31, 5:00AM CST
Cramer says there's nothing special about Archer-Daniels-Midland and prefers AT&T's yield to Altria's.
Jim Cramer's 'Mad Money' Recap: Social, Mobile, Cloud Are Buys
at The Street - Thu Jan 30, 7:19PM CST
Facebook and Google shine with fantastic earnings, Cramer says.
TherapeuticsMD Reports Positive PK Study Results for Its Estradiol Vaginal Capsule VagiCap(TM) (TX 12-004-HR) for Treatment of Vulvar Vaginal Atrophy (VVA)
Business Wire - Tue Jan 28, 6:00AM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's healthcare company ("TherapeuticsMD" or the "Company"
Therapeutics Inc begins Phase 3 clinical trial of TX 12-002-HR for treating secondary amenorrhea in women
M2 - Mon Jan 27, 6:39AM CST
Healthcare company Therapeutics Inc (NYSE MKT:TXMD) reported on Friday the launch of the SPRY Trial to evaluate the safety and efficacy of TX 12-002-HR for the treatment of secondary amenorrhea in women.
TherapeuticsMD Initiates Phase 3 Clinical Trial of Its Progesterone Candidate (TX 12-002-HR) for Treatment of Secondary Amenorrhea
Business Wire - Fri Jan 24, 6:00AM CST
TherapeuticsMD, Inc. (NYSE MKT:TXMD), a women's healthcare company ("TherapeuticsMD" or the "Company"
TherapeuticsMD declares issuance of US patent covering natural combination hormone replacement formulations and therapies
M2 - Fri Jan 24, 4:34AM CST
Women's healthcare company TherapeuticsMD Inc (NYSE MKT: TXMD) announced on Wednesday the issuance of US Patent No 8,633,178 (the '178 patent) entitled 'Natural Combination Hormone Replacement Formulations and Therapies', by the US Patent and Trademark Office (USPTO).
Therapeutics wins US patent for natural combination hormone replacement formulations and therapies
M2 - Thu Jan 23, 5:25AM CST
US-based healthcare company Therapeutics Inc (NYSE MKT:TXMD) reported on Wednesday the receipt of the US Patent No. 8,633,178 (the '178 patent; U.S. Application No. 13/684,002), entitled "Natural Combination Hormone Replacement Formulations and Therapies."
TherapeuticsMD Announces Issuance of U.S. Patent Covering Natural Combination Hormone Replacement Formulations and Therapies, Including TX 12-001-HR
Business Wire - Wed Jan 22, 3:15PM CST
TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's healthcare company ("TherapeuticsMD" or the "Company"
Technical Dossier: Theravance, Alkermes, Cubist Pharma, and TherapeuticsMD
PR Newswire - Wed Jan 08, 7:00AM CST
On Tuesday, January 07, 2014, the U.S. equity market finished on a positive note. The S&P 500 ended the day at 1,837.88, up 0.61%; the Dow Jones Industrial Average closed at 16,530.94, up 0.64%; and the NASDAQ Composite Index finished at 4,153.18, up 0.96%. The S&P 500 Health Care Sector Index gained 1.01% to close the session at 644.13; and the S&P 500 Biotechnology Industry Index closed at 2,766.71, up 0.72%. The S&P 500 Biotechnology Industry Index has gained 10.05% in the previous three months, outperforming the S&P 500, which has gained 9.65% during the same period. Additionally, the S&P 500 Pharmaceuticals Sub Industry Index closed at 491.51, up 0.94%. The major movers in the Health Care Sector included Theravance Inc. (NASDAQ: THRX), Alkermes PLC (NASDAQ: ALKS), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and TherapeuticsMD Inc. (NYSE MKT: TXMD). All these companies are tracked by AAAResearchReports.com. Free technical research on THRX, ALKS, CBST, and TXMD can be downloaded upon signing up at: